BeBetter Med Inc. (SHA:688759)
China · Delayed Price · Currency is CNY 14.95
-1.05 (-6.56%)
At close: Oct 28, 2026
BeBetter Med Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Other Revenue | - | - | - | 0.97 | 0.38 | 0.35 |
| - | - | - | 0.97 | 0.38 | 0.35 | |
Revenue Growth | - | - | - | 157.42% | 7.55% | - |
Cost of Revenue | - | - | - | 0.57 | 0.18 | 0.11 |
Gross Profit | - | - | - | 0.41 | 0.2 | 0.24 |
Selling, General & Admin | 67.8 | 55.86 | 43.1 | 27.39 | 6.15 | 13.9 |
Research & Development | 164.26 | 120.96 | 120.29 | 115.99 | 59.12 | 48.16 |
Other Operating Expenses | 0.61 | 0.31 | 0.2 | 0.06 | 0.02 | -0.05 |
Operating Expenses | 232.7 | 177.44 | 163.88 | 143.46 | 65.35 | 62.05 |
Operating Income | -232.7 | -177.44 | -163.88 | -143.06 | -65.14 | -61.81 |
Interest Expense | -0.01 | -0.1 | -0.14 | -0.12 | - | - |
Interest & Investment Income | 7.77 | 3.84 | 9.48 | 5.24 | 4.78 | 0.69 |
Currency Exchange Gain (Loss) | - | - | - | -0 | -0.02 | - |
Other Non Operating Income (Expenses) | 2.15 | -0.02 | -0.02 | -6.34 | -1.51 | -0.01 |
EBT Excluding Unusual Items | -222.79 | -173.71 | -154.56 | -144.28 | -61.89 | -61.13 |
Gain (Loss) on Sale of Investments | 2.5 | 1.16 | 0.12 | - | - | -0.02 |
Gain (Loss) on Sale of Assets | -0.02 | 0.03 | - | - | - | - |
Asset Writedown | -0 | -0 | -0.01 | - | - | - |
Other Unusual Items | 22.86 | 18.71 | 98.54 | 7.38 | 0.63 | 2.22 |
Pretax Income | -197.46 | -153.83 | -55.91 | -136.9 | -61.26 | -58.94 |
Income Tax Expense | 0.17 | 0.19 | 0.09 | - | - | - |
Net Income | -197.63 | -154.02 | -56 | -136.9 | -61.26 | -58.94 |
Net Income to Common | -197.63 | -154.02 | -56 | -136.9 | -61.26 | -58.94 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 450 | 385 | 350 | 360 | - | - |
Shares Outstanding (Diluted) | 450 | 385 | 350 | 360 | - | - |
Shares Change | - | 10.02% | -2.85% | - | - | - |
EPS (Basic) | -0.44 | -0.40 | -0.16 | -0.38 | - | - |
EPS (Diluted) | -0.44 | -0.40 | -0.16 | -0.38 | - | - |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Free Cash Flow | -201.22 | -113.15 | -108.54 | -106.76 | -42.58 | -5.86 |
Free Cash Flow Per Share | -0.45 | -0.29 | -0.31 | -0.30 | - | - |
Gross Margin | - | - | - | 41.76% | 53.30% | 68.70% |
Operating Margin | - | - | - | -14743.80% | -17282.80% | -17636.55% |
Profit Margin | - | - | - | -14109.31% | -16252.24% | -16815.97% |
Free Cash Flow Margin | - | - | - | -11002.82% | -11295.58% | -1671.95% |
EBITDA | -224.72 | -169.74 | -156.55 | -142 | -64.12 | -60.87 |
D&A For EBITDA | 7.98 | 7.7 | 7.34 | 1.06 | 1.03 | 0.94 |
EBIT | -232.7 | -177.44 | -163.88 | -143.06 | -65.14 | -61.81 |
Revenue as Reported | - | - | - | 0.97 | 0.38 | 0.35 |